Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam

Phase 1CompletedNCT00427505

Novartis22 enrolled

Overview

This is a study to investigate the pharmacokinetics of deferasirox

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

DeferasiroxDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Good health * No evidence of iron deficiency * Weight between 50 and 100 kg * Body Mass Index between 19 and 29 kg/m2 Exclusion Criteria: * Use of certain drugs, herbal remedies or nutrients Other protocol-defined inclusion/exclusion criteria may apply

Outcomes

Primary Outcomes

To assess the effect of deferasirox on the pharmacokinetics of midazolam

Secondary Outcomes

Safety assessed by adverse events (AEs)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.